News &amp; Updates

Treatment with the thyroid hormone beta agonist resmetirom significantly improves qFibrosis continuous values (qFC), categorical stages (qFS), and individual collagen features associated with fibrosis progression at week 52 compared with placebo in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), as shown in the phase III MAESTRO-NASH trial.

Resmetirom shows antifibrotic efficacy in MASH via AI-based quantification

Older age, obesity, T2D linked to hypertension-mediated organ damage

Factors including older age, obesity, and type 2 diabetes (T2D) characterize individuals with subclinical hypertension-mediated organ damage (HMOD) in The Maastricht Study.

Older age, obesity, T2D linked to hypertension-mediated organ damage

Subclinical cardiac remodeling tied to increased cancer risk

A study using data from the MESA* cohort shows an association between subclinical cardiac remodeling and increased risk of cancer.

Subclinical cardiac remodeling tied to increased cancer risk

OS data show promise for risvutatug rezetecan in R/R sarcoma

Longer-term follow-up of the phase II ARTEMIS-002 trial continues to show promising efficacy of risvutatug rezetecan (ris-rez) in relapsed or refractory (R/R) sarcoma, with median overall survival (OS) reaching about 2 years, according to data presented at ESMO TAT Asia 2026.

OS data show promise for risvutatug rezetecan in R/R sarcoma

Post-MI beta-blocker use lowers mortality risk in COPD patients

Beta-blocker therapy following myocardial infarction (MI) reduces the risk of death in patients with comorbid chronic obstructive pulmonary disease (COPD), with the magnitude of benefit similar to that observed in patients without COPD, according to a Danish cohort study.

Post-MI beta-blocker use lowers mortality risk in COPD patients

Vedolizumab induces clinical remission in paediatric patients with UC

Treatment with either low- or high-dose vedolizumab yields high rates of clinical remission in children with moderate-to-severe ulcerative colitis (UC), regardless of weight, according to the phase III KEPLER trial presented at ESPGHAN 2026.

Vedolizumab induces clinical remission in paediatric patients with UC

Bidi smoking, poly-tobacco use contribute to cancer burden

Use of bidi either exclusively or along with other tobacco products carries increased cancer risk, as reported in an observational study in India.

Bidi smoking, poly-tobacco use contribute to cancer burden

Probable OCD prevalent among Singapore’s youth

21 Jul 2026 by

More than one-fifth of young people in Singapore have probable obsessive–compulsive disorder (OCD), according to local research.

Probable OCD prevalent among Singapore’s youth

Early rhythm control reduces CV events in AF patients

Early rhythm control (ERC) is a safe and effective strategy to prevent cardiovascular (CV) events in patients with a recent diagnosis of atrial fibrillation and stroke risk factors with or without chronic kidney disease (CKD), according to a secondary analysis of the EAST-AFNET 4 trial.

Early rhythm control reduces CV events in AF patients

Supplemental O2, NHFO2 improve dyspnoea, exercise tolerance in f-ILD

21 Jul 2026 by

Both acute O2 supplementation and nasal high-flow O2 therapy (NHFO2) result in improvements in exertional dyspnoea and exercise tolerance at “iso-O2 saturation” in severely hypoxemic patients with fibrotic interstitial lung disease (f-ILD), driven primarily by a similar decline in ventilatory requirements, reports a study.

Supplemental O2, NHFO2 improve dyspnoea, exercise tolerance in f-ILD